At present, an effective detecting method for brain function impairment for the patients with the glioma is urgently needed in clinic, because it may help us understand its pathogenesis. This paper proposes a method of combining diffusion tensor tracing technology and 'small world' network. It utilizes the degree of brain function network to study complex network topological properties of the patients with the glioma in temporal lobe area. The experimental results showed that the brain networks of the patients with the glioma of different grades were destroyed compared with those of the normal persons, but the destruction degree is independent of the tumor grades. The distribution of functional connections is index truncated power-law accompanied by significant heterogeneity. Meanwhile, the stronger functional areas of information in the glioma have transferred and there exists lack of language function area and sensory function area.
Download full-text PDF |
Source |
---|
Aim: Many combinations of inflammation-based markers have been reported their prognostic ability. The prognostic value of albumin-to-gama-glutamyltransferase ratio (AGR), an inflammation-related index, has been identified for several cancers. However, the predictive value of AGR for high-grade glioma patients remains unclear.
View Article and Find Full Text PDFAim: This study aims to assess the clinicopathological and prognostic significance of Tim-3, an immune checkpoint molecule, and Rel-B, an NF-κB subunit, in grade 4 diffuse glioma samples and their relationship with each other.
Material And Methods: The demographic, radiologic, prognostic, and treatment data of patients diagnosed with grade 4 diffuse glioma between 2016 and 2019 were reviewed and recorded. Tim-3 and Rel-B were applied to the paraffin-embedded tissues by immunohistochemistry method.
Front Oncol
January 2025
Department of Neurosurgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Tumor Treating Fields (TTFields) has emerged as a significant adjunctive component in the treatment of high-grade gliomas following the EF-14 trial in 2017. The incorporation of TTFields, alongside cyclic temozolomide therapy, has demonstrated improved patient outcomes when the usage exceeds 18 h per day (75% usage). analysis of the EF-14 trial has demonstrated that therapy usage exceeding 90% is associated with an additional benefit, while rates above 50% have also proven effective in literature.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Pediatrics, Children's Healthcare of Atlanta, Atlanta, GA, United States.
Background: Pediatric low-grade gliomas (pLGGs) have an overall survival of over 90%; however, patients harboring a BRAF alteration may have worse outcomes, particularly when treated with classic chemotherapy. Combined BRAF/MEK inhibition following incomplete resection demonstrated improved outcome in BRAF altered pLGG compared to combined carboplatin/vincristine chemotherapy and is now considered the standard FDA-approved treatment for this group of tumors. The aim herein was to investigate the efficacy and tolerability of single agent BRAF inhibitor treatment in BRAF altered pLGG.
View Article and Find Full Text PDFInt J Nanomedicine
January 2025
Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People's Republic of China.
Glioma is the most common primary malignant brain tumor with a poor survival rate. It is characterized by diffuse and invasive growth and heterogeneity, which limits tumor identification and complete resection. Therefore, the precise detection and postoperative adjuvant therapy of gliomas have become increasingly important and urgent.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!